Author

Qiulian Wu

University of Pittsburgh

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1

Frequent Co-Authors

Anahit Hovsepyan· 1 shared Gevorg Karapetyan· 1 shared Jamie Cope· 1 shared Jeremy N. RichiD· 1 shared Jiarui WangiD· 1 shared Laura A. SoltiD· 1 shared Priscilla ChaniD· 1 shared Rex A. MoatsiD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Anahit Hovsepyan

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Advancing Clinical Response Against Glioblastoma: Evaluating SHP1705 CRY2 Activator Efficacy in Preclinical Models and Safety in Phase I Trials

Priscilla Chan, Yoshiko Nagai, Qiulian Wu, Anahit Hovsepyan, Seda Mkhitaryan, Jiarui Wang, Gevorg Karapetyan, Theodore M. Kamenecka, Laura A. Solt, Jamie Cope, Rex A. Moats, Tsuyoshi Hirota, Jeremy N. Rich, Steve A. Kay

This paper evaluates the safety and efficacy of SHP1705, a CRY2 activator, in preclinical models and Phase I trials, showing improved efficacy against GBM stem cells and synergistic effects with a REV-ERB agonist.

Neuro-Oncology · Apr 1, 2025Peer-reviewedCancer Biology